UniChem - An EBI compound structure cross-referencing resource

We have faced for some time some issues with compound integration with ChEMBL - specifically the loading of compound sets into ChEMBL for cross referencing, between for example, ChEBI, PDBe compounds, etc. The ChEMBL update cycle is relatively slow with respect to some other resources, and there is inevitable thrash with compounds not being present, especially for exciting new data. Without doing something different for compound integration, we were starting to face a scenario where we had a compound table with many millions of compounds without any bioactivity data, and following this the inevitable slowdown in searching, etc.

We also had some issues facing us about curation of other people's primary data, changing compound structures, or their rendering, etc.

So, we decided to set up an external system to resolve cross-references between various databases. This is a very simple Standard InChI lookup, containing compounds from resources such as ChEMBL, ChEBI, PDBe, DrugBank, KEGG, BindingDB, PubChem, and so forth. UniChem can also handle versioning of the contained resources. We will be migrating various components of the current ChEMBL interface across to use web services on UniChem, this way, the cross links will always be fresh and correct, and we can focus on curation and optimisation of ChEMBL content. There are some other resources, like ZINC, STITCH, and ChemSpider, for example, that would be great to integrate, if we can get hold of the required data.

The easiest way for us to handle deposition into UniChem is for us to take an ftp: feed of a simple table of resource_id, standard_InChI, and standard_InChI_key.

At the moment, UniChem sits behind our firewall, but if people want to have a play, let us know.

We will write something more specific and detailed, but would welcome thoughts of whether this resolver should be externally facing, and what other resources would be good to integrate?

The image above may or may not be the UniChem logo.

Comments

Michael Kuhn said…

So the idea is that you give UniChem an InChIKey, and get back the identifiers of the source databases? To some extent, this already works in PubChem:
http://www.ncbi.nlm.nih.gov/pcsubstance?term=KEGG%5Bsource%5D%20%20BSYNRYMUTXBXSQ-UHFFFAOYSA-N" Although you don't control the versions, of course.

Regarding STITCH, we're downstream of PubChem and also don't create new interactions that you could integrate into ChEMBL. Therefore, it's probably easiest to leave STITCH out of UniChem and rather link to STITCH via InChIKey:
http://stitch.embl.de/interactions/BSYNRYMUTXBXSQ-UHFFFAOYSA-N

~Michael

25 November 2011 at 12:26

jpo said…

Thanks for the comment. I guess the linking out to STITCH via InChI key is one-way only (or at least practically is one-way).

We should have simple cross reference to STITCH in a future version of the ChEMBL interface.

Longer term we have a plan with UniChem to provide some additional services off this, such as a trivial name/synonym service, etc. Keeping on top of names is a real pain for us, and others do it really well.

27 November 2011 at 10:03

fredrik said…

I think it would be really great with the addition of some vendor databases like emolecules.com. To have the ability to filter ChEMBL based on commercial availability would give great benefits.

/Fredrik

28 November 2011 at 10:43

Unknown said…

You can already get a purchasable subset of ChEMBL via ZINC. Both ChEMBL15 http://zinc.docking.org/pbcs/chembl15 and ChEMBL DrugStore http://zinc.docking.org/pbcs/drugstore. The molecules are in ready-to-dock formats, free to download. We also offer purchasable subsets of many other subsets like IUPHAR, FDA, DrugBank, bindingdb, and also supersets, like all purchasable natural products, metabolites, drugs, in man compounds, etc, etc.

25 February 2013 at 06:26

New SureChEMBL announcement

(Generated with DALL-E 3 ∙ 30 October 2023 at 1:48 pm) We have some very exciting news to report: the new SureChEMBL is now available! Hooray! What is SureChEMBL, you may ask. Good question! In our portfolio of chemical biology services, alongside our established database of bioactivity data for drug-like molecules ChEMBL , our dictionary of annotated small molecule entities ChEBI , and our compound cross-referencing system UniChem , we also deliver a database of annotated patents! Almost 10 years ago , EMBL-EBI acquired the SureChem system of chemically annotated patents and made this freely accessible in the public domain as SureChEMBL. Since then, our team has continued to maintain and deliver SureChEMBL. However, this has become increasingly challenging due to the complexities of the underlying codebase. We were awarded a Wellcome Trust grant in 2021 to completely overhaul SureChEMBL, with a new UI, backend infrastructure, and new f

A python client for accessing ChEMBL web services

Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d

New Drug Approvals - Pt. XVII - Telavancin (Vibativ)

The latest new drug approval, on 11th September 2009 was Telavancin - which was approved for the treatment of adults with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria , including Staphylococcus aureus , both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains. Telavancin is also active against Streptococcus pyogenes , Streptococcus agalactiae , Streptococcus anginosus group (includes S. anginosus, S. intermedius and S. constellatus ) and Enterococcus faecalis (vancomycin susceptible isolates only). Telavancin is a semisynthetic derivative of Vancomycin. Vancomycin itself is a natural product drug, isolated originally from soil samples in Borneo, and is produced by controlled fermentation of Amycolatopsis orientalis - a member of the Actinobacteria . Telavancin has a dual mechanism of action, firstly it inhibits bacterial cell wall synthesis by interfering with the polymerization and cross-linking of peptid

Accessing SureChEMBL data in bulk

It is the peak of the summer (at least in this hemisphere) and many of our readers/users will be on holiday, perhaps on an island enjoying the sea. Luckily, for the rest of us there is still the 'sea' of SureChEMBL data that awaits to be enjoyed and explored for hidden 'treasures' (let me know if I pushed this analogy too far). See here and here for a reminder of SureChEMBL is and what it does. This wealth of (big) data can be accessed via the SureChEMBL interface , where users can submit quite sophisticated and granular queries by combining: i) Lucene fields against full-text and bibliographic metadata and ii) advanced structure query features against the annotated compound corpus. Examples of such queries will be the topic of a future post. Once the search results are back, users can browse through and export the chemistry from the patent(s) of interest. In addition to this functionality, we've been receiving user requests for local (behind the

Multi-task neural network on ChEMBL with PyTorch 1.0 and RDKit

Update: KNIME protocol with the model available thanks to Greg Landrum. Update: New code to train the model and ONNX exported trained models available in github . The use and application of multi-task neural networks is growing rapidly in cheminformatics and drug discovery. Examples can be found in the following publications: - Deep Learning as an Opportunity in VirtualScreening - Massively Multitask Networks for Drug Discovery - Beyond the hype: deep neural networks outperform established methods using a ChEMBL bioactivity benchmark set But what is a multi-task neural network? In short, it's a kind of neural network architecture that can optimise multiple classification/regression problems at the same time while taking advantage of their shared description. This blogpost gives a great overview of their architecture. All networks in references above implement the hard parameter sharing approach. So, having a set of activities relating targets and molecules we can tra

The ChEMBL-og

Search This Blog